TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.

J M Weiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.